Shenzhen New Industries Biomedical Engineering Co., Ltd. (SHE:300832)
China flag China · Delayed Price · Currency is CNY
60.55
+1.47 (2.49%)
Nov 13, 2026, 3:04 PM CST

SHE:300832 Cash Flow Statement

Millions CNY. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Net Income
1,8061,6201,8281,6541,328973.7
Depreciation & Amortization
196.4196.4185.61154.33116.4897
Other Amortization
38.2138.2133.4524.8715.6813.4
Loss (Gain) From Sale of Assets
---0.02-0.05-0.62-0.1
Asset Writedown & Restructuring Costs
1.641.640.411.521.521.86
Loss (Gain) From Sale of Investments
-77.14-77.14-118.47-92.94-76.95-71.67
Provision & Write-off of Bad Debts
20.0420.0428.0110.7814.32-7.37
Other Operating Activities
307.4844.9789.84-9.03-50.4126.55
Change in Accounts Receivable
-226.16-226.16-612.94-277.18-240.16-154.66
Change in Inventory
110.78110.78-382.5-136.49-229.95-227.73
Change in Accounts Payable
-211.37-211.37304.2184.02162.1210.03
Change in Other Net Operating Assets
-----80.7193.88
Operating Cash Flow
1,9711,5221,3561,418962.39773.22
Operating Cash Flow Growth
34.74%12.23%-4.36%47.37%24.47%-20.83%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Capital Expenditures
-321.94-311.44-439.2-322.2-403.22-342.94
Sale of Property, Plant & Equipment
0.040.040.110.090.660.24
Sale (Purchase) of Intangibles
-----16.62-
Investment in Securities
-548.7-132.79-361.86-53.47-261.5-634.54
Other Investing Activities
95.9330.7995.884.8586.9652.67
Investing Cash Flow
-774.67-413.4-705.15-290.73-593.72-924.57

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Long-Term Debt Repaid
--4.61-4.24-4.11-4.05-3.59
Lease Payments
-4.61-4.61-4.24-4.11-4.05-3.59
Net Debt Issued (Repaid)
-4.61-4.61-4.24-4.11-4.05-3.59
Issuance of Common Stock
-----129.56
Repurchase of Common Stock
----16.29-21.62-
Common Dividends Paid
-935.57-1,022-785.96-548.21-471.78-413.4
Other Financing Activities
-199.9----0
Financing Cash Flow
-1,140-1,026-790.2-568.61-497.45-287.43

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Foreign Exchange Rate Adjustments
-62.07-6.0712.678.69-9.13-14
Net Cash Flow
-6.1376.5-126.25567.66-137.9-452.78

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Free Cash Flow
1,6491,211917.241,096559.17430.28
Free Cash Flow Growth
46.48%32.02%-16.32%96.02%29.96%-40.39%
Free Cash Flow Margin
34.00%26.46%20.22%27.89%18.35%16.90%
Free Cash Flow Per Share
2.101.541.171.400.710.55
Levered Free Cash Flow
551.59789.99626.87705.91198.4213.19
Unlevered Free Cash Flow
551.84790.32627.14706.18198.57213.29
Free Cash Flow After Leases
1,6441,2069131,092555.12426.69

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Cash Income Tax Paid
457.89431.05296.84192.8280.06200.54
Change in Working Capital
-321.97-321.97-690.86-324.83-385.54-260.16